<DOC>
	<DOC>NCT00364468</DOC>
	<brief_summary>To assess the duration of severe neutropenia in cycle 1 of chemotherapy after treatment with a single injection of KRN125 or multiple daily injections of filgrastim.</brief_summary>
	<brief_title>Dose Finding Study of KRN125 (Pegfilgrastim) for Treatment of Neutropenic Patients</brief_title>
	<detailed_description />
	<mesh_term>Neutropenia</mesh_term>
	<criteria>patients diagnosed as malignant lymphoma patients who were refractory to anthracycline or anthraquinone containing chemotherapy patients who are going to receive ESHAP or CHASE treatment regimen ECOG performance status =&lt; 2 patients who have appropriate bone marrow, hepatic and renal functions written informed consent double cancer history of bone marrow transplantation or PBSCT more than 2 prior chemotherapy regimens primary hematologic disease such as myelodysplastic syndrome previous radiotherapy within 4 weeks of enrollment woman of childbearing potential who were either pregnant, breast feeding patients who participated in other clinical trials within the last 4 weeks of enrollment</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>74 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>pegfilgrastim</keyword>
	<keyword>neutropenia</keyword>
	<keyword>cancer patients</keyword>
	<keyword>lymphoma</keyword>
</DOC>